Octreo (Octreotide)

Octreotide, the active ingredient in Octreo, is a somatostatin analog presented as a formulation for injection use. It is employed to manage hormone‑secreting tumours and related endocrine disorders in adults.

GNH USA supplies Octreo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Octreotide is a synthetic analogue of somatostatin that modulates neuroendocrine activity in several disease states.

- Acromegaly: reduces excess growth hormone production and improves clinical symptoms. - Carcinoid syndrome: controls flushing and diarrhoea associated with serotonin‑rich tumours. - VIPoma/Medullary thyroid carcinoma: decreases vaso‑active intestinal peptide‑driven secretions and related hormonal excess. - Preventive control of postoperative post‑operative post‑operative post surgical bleeding of the pituitary g . - Management of refractory diabetes insulin pump failure (though off‑label). -  

Octce